“The financing is structured in three tranches tied to the progress and outcome of the company’s pivotal ENIGMA-TRS studies. An initial tranche of up to €15 million will be raised through the subscription of up to 779,624 newly issued shares at a price of €19.24 per share. A second tranche of €11 million will be subscribed as the ENIGMA-TRS 1 and 2 studies progress toward their 12-week results, expected in the fourth quarter of this year and no later than November 30, 2026, with pricing determined by an agreed formula”.
4 Likes
Hopefully this drug will live up to it’s promise at least in part or better yet in full.
1 Like
It’s said to be even better than Cobenfy. The problem is that it’s not taken alone; it’s used in conjunction with other medications.
I wonder if they going to test it on it’s own or is it absolutely necessary to use ap’s on the side. After all it was advertised as a compound which attacks the condition at it’s source.
1 Like